^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Neofordex (dexamethasone acetate high-dose)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CTRS Laboratories, Zaphyr Pharma
Drug class:
GCR agonist
Related drugs:
22d
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov)
P2, N=96, Suspended, Hackensack Meridian Health | Trial completion date: Jan 2025 --> Jan 2026 | Recruiting --> Suspended | Trial primary completion date: Jan 2025 --> Jan 2026
Trial completion date • Trial suspension • Trial primary completion date
|
Xpovio (selinexor) • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Neofordex (dexamethasone acetate high-dose)
3ms
FREEDOM: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone (clinicaltrials.gov)
P3, N=318, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting
Enrollment open • Head-to-Head • Metastases
|
carfilzomib • dexamethasone • Neofordex (dexamethasone acetate high-dose)
7ms
FREEDOM: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone (clinicaltrials.gov)
P3, N=318, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
New P3 trial • Head-to-Head • Metastases
|
carfilzomib • dexamethasone • Neofordex (dexamethasone acetate high-dose)
11ms
SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov)
P2, N=50, Active, not recruiting, Ida Bruun Kristensen | Recruiting --> Active, not recruiting
Enrollment closed
|
lenalidomide • bortezomib • Xpovio (selinexor) • dexamethasone • Neofordex (dexamethasone acetate high-dose)
1year
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov)
P2, N=96, Recruiting, Hackensack Meridian Health | Phase classification: P2b --> P2 | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
Phase classification • Trial completion date • Trial primary completion date • Combination therapy
|
Xpovio (selinexor) • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Neofordex (dexamethasone acetate high-dose)
almost2years
SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov)
P2, N=50, Recruiting, Ida Bruun Kristensen | N=100 --> 50
Enrollment change
|
lenalidomide • bortezomib • Xpovio (selinexor) • dexamethasone • Neofordex (dexamethasone acetate high-dose)
Share via
